Compare Amphastar Pharmaceuticals Inc (AMPH) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Petróleo Brasileiro SA — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Petróleo Brasileiro SA trades at $17.42 (market cap $105.14B). The key difference: Petróleo Brasileiro SA is far larger — about 127.3× Amphastar Pharmaceuticals Inc's market cap, and Petróleo Brasileiro SA pays a 10.18% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | PBR | |
|---|---|---|
Market Cap | $826.08M | $105.14B |
Sector | Health | Technology |
52-Week High | $30.81 | $22.03 |
52-Week Low | $16.87 | $11.54 |
Enterprise Value | $1.22B | $167.68B |
Dividend Yield | — | 10.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Petrobras (PBR) trades at $17.32, up 1.7% with bullish technical signals and strong fundamentals. The stock shows attractive valuation metrics with P/E of 5.52 and ROE of 24.94%, supported by robust cash flow generation of $197.5B in 2025. Recent developments include strategic partnerships with Pemex and renewable energy investments, while maintaining consistent dividend payments.
PBR presents compelling value with significant upside to the $23.90 consensus target, though faces risks from commodity volatility and recent earnings miss. The company's production growth and cost discipline support long-term investment case, but investors should monitor execution on new projects and oil price sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
